Completed NA INTERVENTIONAL NCT01321502

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fed Conditions

Sponsor: Roxane Laboratories

Conditions Herpes

Interventions famciclovir

Updated 7 times since 2017 Last updated: Jan 19, 2018 Started: Jul 31, 2007 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01321502, this NA trial focuses on Herpes and remains completed. Sponsored by Roxane Laboratories, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2018 [monthly]

Completed NA

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxane Laboratories

Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hackensack, United States